Mycoplasma Galliscepticum Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

Mycoplasma Galliscepticum Vaccine Market

The future of the global mycoplasma galliscepticum vaccine market looks promising with opportunities in the veterinary pharmacy and online sale markets. The global mycoplasma galliscepticum vaccine market is expected to reach an estimated $554.4 million by 2035 from $310.9 million in 2027 with a CAGR of 6.4% from 2027 to 2035. The major drivers for this market are the rising poultry disease outbreaks and the growing poultry industry.

• Lucintel forecasts that, within the type category, live is expected to witness higher growth over the forecast period due to rising demand for more effective and longer-lasting immunity in poultry against mycoplasma gallisepticum infections.
• Within the application category, online sale is expected to witness the higher growth due to growing preference for e-commerce platforms offering competitive pricing, bulk purchasing options, and home delivery services.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to a large, established poultry farming industry, coupled with veterinary vaccination adoption.

Emerging Trends in Mycoplasma Galliscepticum Vaccine Market

From 2025 to 2027, prevention of disease control programs through vaccines will be the biggest market opportunity for poultry producers due to increased biosecurity requirements, greater variation in disease occurrence, and potential limitations to the use of antibiotics. According to Lucintel, there will be a demand for vaccines that can be scaled based on the local poultry economy, along with more advanced diagnostics.

• Sustainability: Poultry integrators will lead a shift to scalable vaccination programs to reduce the reliance on antibiotics and production losses during 2025 to 2027. Three live vaccines (F, ts-11, and 6/85) will provide diverse prevention programs to poultry integrators. This shift will be furthered by retailers and regulators addressing the need for measurable antimicrobial stewardship along the supply chain.
• Precision Health: Starting in 2025, poultry integrators are expected to make decisions based on flock testing in combination with production data and PCR surveillance, and/or serology. Diagnostic timing will determine whether vaccination will occur prior to exposure. During the next 3 to 5 years, the use of data will lead to a more efficacious vaccination program.
• Thermostable Delivery: During 2025-2027, vaccine delivery systems that are thermostable will be prioritized by vaccine developers to control logistics for hot and/or remote climates. Temperature excursions will remain a challenge for live biologics. Vaccine delivery systems that are thermostable will be adopted more easily where the uptake of the cold chain is suboptimal.
• Regional Manufacturing: From 2025 to 2027, disruptions in the supply chain will lead poultry companies and governments to have a preference for local or regional vaccine production. Shortening the time to replenish vaccine supply will become particularly important to protect multisite production. This will reshape how companies bid and lead to more technology alliances and less reliance on a few exporting countries.
• Integrated Protection: Mycoplasma vaccination integrated with breeder management, hatchery control, along with all-in/all-out biosecurity will be available as a package deal from 2025-2027. Vaccination will no longer be an option as a standalone purchase. The approach will, in the next three to five years, have an impact on market value, as the outcome of the flock, as opposed to the price of the product, will determine a buyer's decision.

The market for mycoplasma gallisepticum vaccine is now moving away from routine flock treatments. The competitive position will be regional manufacturing, better control, and differentiation. Relatively high density of poultry in conjunction with increased scrutiny on antibiotics should maintain the strongest current demand. Trust of the suppliers will increase if the combination of the validated efficacy and convenience of administration are achieved. Price of vaccines on their own will not create market share in the fragmented global market.

Recent Developments in the Mycoplasma Galliscepticum Vaccine Market

Mycoplasma gallisepticum vaccine activity will continue to increase from 2025-2027 as industry producers implement more extensive disease control programs. As antibiotic use decreases, Lucintel predicts highest demand for the vaccine in the commercial layer and breeder sectors. Suppliers will compete for this market based on ease of administration, strain performance, and more extensive regulatory coverage within regional markets.

• Growth of Live and Inactivated Poultry Vaccine Production: Associated manufacturing capacity will increase based on forecasts that predict larger global poultry production (forecast at >140 million tons for 2025) and increased flock sizes. This will provide improved security of supply and reduce lead time over the next 3 to 5 years.
• Expansion of Partnerships: Vaccine production companies will collaborate directly with vaccine distributors and veterinary laboratories, as well as producer integrators, to help refine surveillance programs and develop region-specific vaccination protocols. A control program for more than 20 countries spanning the majority of the broiler producing region, which started in January 2025, is indicative of the scope of regional efforts to improve control of poultry diseases.
• Technology Innovation: Competitors are pursuing innovation of live vaccine technology, while others have begun offering spray delivery and simplified combination vaccines. Single dose protocols with reported administration coverage of 100% have begun to be used, in June 2025.
• Government Approvals: Regulatory Agencies have been increasing their review of vaccine quality, safety, and resistance to microorganisms. Vaccines for use in poultry have seen the greatest effects from these changes. By February 2026, regional approvals required data from three controlled efficacy studies. Improving requirements will allow companies to distinguish themselves through product documentation and able clinical trial conduct.
• Major Contracts: Longer term supply agreements have been developed by integrated poultry companies to secure vaccine supply during expected outbreaks. In August 2025, one procurement agreement was for 5 million doses for breeder and layer operations. These agreements are expected to shape the market within the supplier capacity to provide consistent batches, and reliable delivery, and technical support.

There will be an expected correlation of demand to the density of the local flocks and pressures from regional diseases and the cost of production with no antibiotic use. Live vaccines will have increased use in the markets if producers accept tighter restrictions on product use. Inactivated vaccines have potential in breeder programs. In order to gain market share, stable supplying of product and field support are critical. Regulatory framework and not marketing will dictate the adoption of vaccines within the major poultry market regions.

Strategic Growth Opportunities in the Mycoplasma Galliscepticum Vaccine Market

The market for the mycoplasma galliscepticum vaccine is expanding as poultry producers deal with more restrictive biosecurity regulations and the constant threat of avian flu outbreaks, combined with more poultry per broiler house. For the next three years, there will be a shift towards vaccines that will help decrease the prevalence of these diseases on a regional level and enhance production efficiency. Lucintel sees this shift as the creation of new markets that go past just the layer and breeder segments.

• Broiler Application: Vaccines designed to protect broiler chickens from respiratory disease will help reduce respiratory losses caused by broiler intensive production. Increasing integration of vaccination in broiler farms is expected to increase as more integrators notice a decrease in mortality and an increase in feed efficiency and reduced disruptive treatments.
• Premium Recombinants: Safety and longer duration of protection command higher prices. More than200 veterinary medicinal products containing immunological agents were authorized in the EU in March 2025. A preference for premium vaccines, designed to protect against respiratory diseases, is expected in large farms in the next three to five years.
• Increased Focus on Developing Markets: High growth countries in Southeast Asia, Latin America, and some countries in Africa have the biggest potential in the near term for local vaccine distribution, training, and veterinary support. In July 2025, Brazil's poultry meat exports were over 400,000 tons. The region will continue to grow as commercial poultry farms in the area continue to improve and increase the professionalization of disease surveillance.
• Digital Vaccination Services: Connected flock records, diagnostic services, and aid treatment services can provide the outcome-based selling of vaccines. In October 2025, precision-livestock platforms were tracking millions of birds across commercial operations. These services will shift purchasing from product price to verified reductions in respiratory disease and production loss.
• Customized, Regional Programs: Producers are beginning to demand vaccines tailored to local disease challenges, farm density, and maternal-antibodies. In February 2026, WOAH reported that poultry disease surveillance was being performed by over 180 countries. Tailored programs will increase recurring revenue from diagnostics, consultations, and scheduled revaccinations.

Producers will prefer suppliers that offer a combination of reliable efficacy, field support, regulatory, and data services. The largest market potential is likely to come from integrated services as opposed to stand-alone vaccinations. Companies can offer improvements in flock health while preserving margins by offering products tailored to evolving broiler systems and marketing them to emerging regions. Success will be dependent on demonstrating improved production at the farm level.

Mycoplasma Galliscepticum Vaccine Market Drivers and Challenges

The growth of the market for the Mycoplasma galliscepticum vaccine is directly related to factors such as prevalence of poultry diseases, production expansion, advances in vaccine technology, and the regulatory framework and pricing environment. Market uptake is supported by the trend to produce healthier flocks, as well as the trend to reduce the use of antibiotics, while market obstacles include the complexity of production and the uneven veterinary infrastructure. Lucintel identify technology, economics, sustainability, and regulation as the major market influences.

The factors responsible for driving this market include :

• Increasing Importance of Prevention of Poultry Diseases: The vaccination of commercial poultry is becoming increasingly important due to the economic loss from disease caused by high mortality and the loss of productivity. With an estimated annual global poultry meat production of over 140 million tonnes in January 2025, it is clear that on-farm practices improvement is warranted due to the economic importance of flock health. Over the next three to five years, the demand for preventative vaccines will remain strong due to the intensive farming of poultry.
• Vaccine Innovation: There are new technologies that offer improved protection and vaccine administration flexibility and coverage. By March 2025 poultry vaccination programs included combinations for the control of three or more diseases. Within the next three to five years, the overarching influence of these innovations is expected to be reduced labor, improved and sustained immunity, and wide acceptance of large-scale production.
• Restrictions on The Use and Availability of Antibiotics: There is increasing market acceptance of vaccination for prevention of diseases as a complement to the control of antibiotics. Restriction on the use of antibiotics of importance in medicine is also a driving factor for vaccination. In February 2025, the World Health Organization continues to promote the reduction of antimicrobial resistance in the production of food animals. of importance, the demand for antibiotic-free poultry will continue to drive vaccination.
• Expansion of Commercial Poultry Farming: Increased consumer demand for poultry meat and eggs creates an opportunity for larger and more professionally run poultry farms. As of April 2025, poultry ranked among the most prominent categories of animal protein consumed across the world with annual production in the range of 100 million metric tons. Mass production of poultry enables farms to implement certain vaccination programs on a large scale, creating a positive impact on market growth by improving biosecurity and predictability of supply.
• Supply Efficiency and Market Growth: Improvements in cold-chain logistics and regional automation of filling, dosing, and packaging processes result in less vaccine wastage. By June 2025, automated biologics manufacturing systems had increased dosage capacity to thousands per hour. Improved supply will help the market in the next three to five years through a substantial decrease in cost and higher confidence in supply in new regions of poultry production.

The challenges facing this market include:

• Difficulty of Epidemiological Diagnosis: Mycoplasma galliscepticum produce symptoms similar to respiratory infections and are therefore difficult to diagnose. In January 2025, poultry respiratory infections were diagnosed as a result of multiple laboratory tests and confirmed by the identification of a specific pathogen. Over the next three to five years, the decision to vaccinate will depend on the uncertainty of diagnostic accuracy and low confidence in the performance of the products, resulting in users adopting broader, more comprehensive disease control strategies rather than targeted vaccination.
• Cold-Chain and Infrastructure Challenges: All but the largest farms, even in developed markets, lack adequate cold infrastructure, refrigeration, skilled vaccinators, and appropriate distribution networks. By May 2025, most vet biologics required temperature controlled storage in the range of 2°C - 8°C. These gaps in infrastructure will continue to inhibit market penetration by increasing spoilage, increasing logistics costs, and reducing access for geographically dispersed poultry farmers.
• Regulatory and Cost Challenges: Regulatory approvals, appropriate strain efficacy, and price will influence market growth. In August 2025, vet vaccine approvals in most jurisdictions still required a lengthy safety and efficacy evaluation that could easily take more than a year. It is expected that over the next 3-5 years, approval delays (given the current budget constraints of producers) will limit the market to the established suppliers.

It is expected that the market for Mycoplasma galliscepticum vaccine will grow as production of poultry increases, disease prevention practices grow, and as markets shift toward reduced poultry antibiotic use and increased vaccine use. The complexity of diagnostics, and the weaker infrastructure and regulatory systems and the cost of vaccination will constrain market growth. The market leaders who support stable vaccines, practical administration, cold chain supply and have evidence based efficacy will be best positioned for the market. Further improvements will be realized with partnerships with public agencies and increased focus on adoption within the veterinary laboratories and poultry integrators. During the next three to five years, it is expected that growth will occur specifically in the developed countries, where the market is expected to be more advanced, and the developing nations where the market is expected to focus on low cost vaccination.

List of Mycoplasma Galliscepticum Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies mycoplasma galliscepticum vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mycoplasma galliscepticum vaccine market companies profiled in this report include-

• Merck
• Ceva
• Zoetis
• Boehringer Ingelheim
• Elanco
• Shandong Huahong Biological Engineering

Mycoplasma Galliscepticum Vaccine Market by Segment

The study includes a forecast for the global mycoplasma galliscepticum vaccine market by type, application, and region.

Mycoplasma Galliscepticum Vaccine Market by Type [Value ($B) from 2019 to 2035]:

• Live
• Inactivated

Mycoplasma Galliscepticum Vaccine Market by Application [Value ($B) from 2019 to 2035]:

• Veterinary Pharmacy
• Online Sale
• Others

Mycoplasma Galliscepticum Vaccine Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Mycoplasma Galliscepticum Vaccine Market

The market of mycoplasma gallisepticum vaccines is being structured by the combination of factors such as the adoption of advanced poultry biosecurity, regional manufacturing, and modified poultry disease control programs. From 2025 to 2027, suppliers will focus on combination vaccines, local production, and compliance with regulatory requirements. According to Lucintel's latest report, these changes are creating a demand window that maintains the discrepancies at the regional level.

• United States: Regulatory unification and the establishment of manufacturing facilities within the country will continue. Zoetis reported revenues of $9.5 billion in 2025 and continued investments within the animal health sector (February 2026), while the USDA APHIS maintained its control over licensing of poultry vaccines (both live and inactivated). This foreseeable approval process is likely to attract vertically integrated producers to create standardized vaccination programs over the next three to five years.
• China: The government's focus is on the control and oversight of veterinary biologics and the security of the domestic supply. In 2025 (January), the Ministry of Agriculture and Rural Affairs of China published 21 mandatory categories of animal disease vaccinations, while domestic manufacturing was providing approvals for poultry products. Local vaccines for mycoplasma will be the favored option and import reliance will be lowered.
• Germany: Advanced biological production will support the European manufacturing. Boehringer Ingelheim spent over €1 billion on 2025 animal health research and production with commitments for manufacturing projects as well as compliance of Regulation 2019/6. Combining capacity investment with strict documentation will strengthen supply of high quality, traceable vaccines.
• India: India's domestic vaccine manufacturing companies continue to bolster their regulatory frameworks and capacity. India's livestock authorities continue to support the prevention of bird flu or protection for poultry through their respective state programs. This should improve local supply and potentially improve adoption throughout commercial and contract poultry operations.
• Japan: Japan's government continues to tie poultry biosecurity to policies against highly pathogenic avian influenza. The Ministry of Agriculture Japan reported 19 outbreaks of highly pathogenic influenza avian infections in poultry during the 2025-2026 crop year (February 2026), resulting in a re-imposition of controls and surveillance. This is expected to sustain the continued demand for vaccine programs and verified diagnostic programs.

Features of the Global Mycoplasma Galliscepticum Vaccine Market

• Market Size Estimates: mycoplasma galliscepticum vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: mycoplasma galliscepticum vaccine market size by type, application, and region in terms of value ($B).
• Regional Analysis: mycoplasma galliscepticum vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the mycoplasma galliscepticum vaccine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mycoplasma galliscepticum vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the mycoplasma galliscepticum vaccine market by type (live and inactivated), application (veterinary pharmacy, online sale, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?